Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis
Myeloproliferative neoplasm (MPN)-associated myelofibrosis is a MPN characterized by bone marrow fibrosis, cytopenias, splenomegaly and constitutional symptoms. Pomalidomide, an immune-modifying drug, is reported to improve anaemia and thrombocytopenia in some patients with MPN-associated myelofibro...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2017
|
| In: |
Leukemia
Year: 2016, Jahrgang: 31, Heft: 4, Pages: 889-895 |
| ISSN: | 1476-5551 |
| DOI: | 10.1038/leu.2016.299 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1038/leu.2016.299 Verlag, Volltext: https://www.nature.com/articles/leu2016299 
|
| Verfasserangaben: | R.F. Schlenk, F. Stegelmann, A. Reiter, E. Jost, N. Gattermann, H. Hebart, C. Waller, A. Hochhaus, U. Platzbecker, P. Schafhausen, I.W. Blau, W. Verbeek, F.H. Heidel, M. Werner, H. Kreipe, V. Teleanu, A. Benner, H. Döhner, M. Grießhammer and K. Döhner |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1574980971 | ||
| 003 | DE-627 | ||
| 005 | 20230427042858.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180511r20172016xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/leu.2016.299 |2 doi | |
| 035 | |a (DE-627)1574980971 | ||
| 035 | |a (DE-576)504980971 | ||
| 035 | |a (DE-599)BSZ504980971 | ||
| 035 | |a (OCoLC)1341009526 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schlenk, Richard Friedrich |d 1965- |e VerfasserIn |0 (DE-588)129025380 |0 (DE-627)387778004 |0 (DE-576)297454102 |4 aut | |
| 245 | 1 | 0 | |a Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis |c R.F. Schlenk, F. Stegelmann, A. Reiter, E. Jost, N. Gattermann, H. Hebart, C. Waller, A. Hochhaus, U. Platzbecker, P. Schafhausen, I.W. Blau, W. Verbeek, F.H. Heidel, M. Werner, H. Kreipe, V. Teleanu, A. Benner, H. Döhner, M. Grießhammer and K. Döhner |
| 264 | 1 | |c 2017 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 11.05.2018 | ||
| 500 | |a Advance online publication, 29 November 2016 | ||
| 520 | |a Myeloproliferative neoplasm (MPN)-associated myelofibrosis is a MPN characterized by bone marrow fibrosis, cytopenias, splenomegaly and constitutional symptoms. Pomalidomide, an immune-modifying drug, is reported to improve anaemia and thrombocytopenia in some patients with MPN-associated myelofibrosis. We designed a phase 2 study of pomalidomide in patients with MPN-associated myelofibrosis and anaemia and/or thrombocytopenia and/or neutropenia. Subjects received pomalidomide 2.0 mg/day in cohort 1 (n=38) or 0.5 mg/day in cohort 2 (n=58). Prednisolone was added if there was no response after 3 months in cohort 1 and based on up-front randomization in cohort 2 if there was no response at 3 or 6 months. Response rates were 39% (95% confidence interval (CI), 26-55%) in cohort 1 and 24% (95% CI, 15-37%) in cohort 2. In a multivariable logistic regression model pomalidomide at 2.0 mg/day (odds ratio (OR), 2.62; 95% CI, 1.00-6.87; P=0.05) and mutated TET2 (OR, 5.07; 95% CI, 1.16-22.17; P=0.03) were significantly associated with responses. Median duration of responses was 13.0 months (range 0.9-52.7). There was no significant difference in response rates or duration in subjects receiving or not receiving prednisolone. Clinical trial MPNSG 01-09 is registered at ClinicalTrials.gov (NCT00949364) and clinicaltrialsregister.eu (EudraCT Number: 2009-010738-23) | ||
| 534 | |c 2016 | ||
| 700 | 1 | |a Reiter, Andreas |d 1964- |e VerfasserIn |0 (DE-588)172629551 |0 (DE-627)697563766 |0 (DE-576)133488594 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia |d London : Springer Nature, 1997 |g 31(2017), 4, Seite 889-895 |h Online-Ressource |w (DE-627)32046699X |w (DE-600)2008023-2 |w (DE-576)094139733 |x 1476-5551 |7 nnas |a Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis |
| 773 | 1 | 8 | |g volume:31 |g year:2017 |g number:4 |g pages:889-895 |g extent:7 |a Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/leu.2016.299 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://www.nature.com/articles/leu2016299 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180511 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 172629551 |a Reiter, Andreas |m 172629551:Reiter, Andreas |d 60000 |d 61200 |e 60000PR172629551 |e 61200PR172629551 |k 0/60000/ |k 1/60000/61200/ |p 3 | ||
| 998 | |g 129025380 |a Schlenk, Richard Friedrich |m 129025380:Schlenk, Richard Friedrich |d 50000 |e 50000PS129025380 |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1574980971 |e 3009135610 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"family":"Schlenk","given":"Richard Friedrich","roleDisplay":"VerfasserIn","role":"aut","display":"Schlenk, Richard Friedrich"},{"roleDisplay":"VerfasserIn","role":"aut","display":"Reiter, Andreas","given":"Andreas","family":"Reiter"}],"note":["Gesehen am 11.05.2018","Advance online publication, 29 November 2016"],"language":["eng"],"recId":"1574980971","physDesc":[{"extent":"7 S."}],"relHost":[{"type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["Nachgewiesen 11.1997 -"],"disp":"Pomalidomide in myeloproliferative neoplasm-associated myelofibrosisLeukemia","title":[{"title_sort":"Leukemia","title":"Leukemia","subtitle":"normal and malignant hemopoiesis ; a peer-reviewed journal"}],"id":{"eki":["32046699X"],"issn":["1476-5551"],"zdb":["2008023-2"]},"origin":[{"dateIssuedDisp":"1997-","dateIssuedKey":"1997","publisher":"Springer Nature ; Stockton Press ; Nature Publ. Group","publisherPlace":"London ; Basingstoke [u.a.] ; Basingstoke"}],"part":{"extent":"7","year":"2017","pages":"889-895","volume":"31","issue":"4","text":"31(2017), 4, Seite 889-895"},"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"recId":"32046699X","note":["Gesehen am 15.03.04"]}],"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"2017"}],"id":{"doi":["10.1038/leu.2016.299"],"eki":["1574980971"]},"name":{"displayForm":["R.F. Schlenk, F. Stegelmann, A. Reiter, E. Jost, N. Gattermann, H. Hebart, C. Waller, A. Hochhaus, U. Platzbecker, P. Schafhausen, I.W. Blau, W. Verbeek, F.H. Heidel, M. Werner, H. Kreipe, V. Teleanu, A. Benner, H. Döhner, M. Grießhammer and K. Döhner"]},"title":[{"title":"Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis","title_sort":"Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis"}],"type":{"media":"Online-Ressource","bibl":"article-journal"}} | ||
| SRT | |a SCHLENKRICPOMALIDOMI2017 | ||